A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Merck Sharp & Dohme LLC
RemeGen Co., Ltd.
UNICANCER
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Alliance for Clinical Trials in Oncology
Ruijin Hospital
Shanghai JMT-Bio Inc.
Peking University
Jiangsu HengRui Medicine Co., Ltd.
RemeGen Co., Ltd.
Sun Yat-sen University
Sun Yat-sen University
NRG Oncology
Ukrainian Society of Clinical Oncology
Tata Memorial Centre
Australasian Gastro-Intestinal Trials Group
Oslo University Hospital
Sun Yat-sen University
Ono Pharmaceutical Co. Ltd
Fujian Cancer Hospital
Shanghai University of Traditional Chinese Medicine
Bristol-Myers Squibb
Qilu Pharmaceutical Co., Ltd.
University of California, San Francisco
Zhejiang University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hebei Medical University
Ruijin Hospital
Blokhin's Russian Cancer Research Center
UNICANCER
Odense University Hospital
Krankenhaus Nordwest
Hebei Medical University
Celgene
Third Military Medical University
Krankenhaus Nordwest
Guangxi Medical University
Guangxi Medical University
Guangxi Medical University
University of Birmingham
Sichuan Provincial People's Hospital
State Key Laboratory of Cancer Biology
European Organisation for Research and Treatment of Cancer - EORTC
AstraZeneca
Federation Francophone de Cancerologie Digestive
UNICANCER
Fudan University
Sirtex Medical
Sun Yat-sen University